Why did UnitedHealth stock fall 20%? What did President Trump say about 2027 Medicare Rates? What does a UnitedHealth stock crash mean for patients and investors?
Policy shifts in Medicare Advantage ripple through the healthcare ecosystem. Today, January 27, 2026, UnitedHealth Group’s stock19.57%, closing at $282.83 after shedding $68.81 per share, erasing roughly $80 billion in market capitalization.
This dramatic drop, the company’s worst single-day performance in years, stemmed from a toxic mix of disappointing Q4 2025 earnings and a bombshell: the Trump administration’s proposal for essentially flat government Medicare payment rates in 2027. Investors fled as the news highlighted deepening profitability pressures amid surging medical utilization trends. But the real story lies in the policy mechanics driving this crash—a web of regulatory tweaks aimed at curbing overpayments.Medicare Advantage, also known as Medicare Part C, represents a private-sector alternative to traditional Original Medicare . Offered by Medicare-approved insurance companies, these plans must cover all hospital and medical benefits at least as comprehensively as Original Medicare, but they often bundle in prescription drug coverage and extras like dental, vision, hearing aids, gym memberships, and transportation to appointments. The key trade-off: While many plans feature lower out-of-pocket maximums and reduced copays, beneficiaries typically must use in-network providers , which can limit choice and require referrals or prior authorizations—contrasting with original Medicare’s broader provider access. As enrollment surpasses half of Medicare beneficiaries, these managed-care models aim to deliver value through coordinated care, though critics highlight network restrictions and variable plan performance year to year.The crux of the UnitedHealth crash lies in the Centers for Medicare & Medicaid Services’ Advance Notice for Calendar Year 2027 Medicare Advantage capitation rates,a net average payment increase of just 0.09%, translating to about $700 million industry-wide—far below the 2-3% growth needed to offset inflation and cost trends. This "flatlining" adjustment reflects underlying cost trends, 2026 quality ratings, and risk model revisions, but nets down to near-zero after offsets.This is far less than what Wall Street and the insurance companies projected or expected. Shares are also down for CVS and Humana.revealed that Medicare Advantage insurers, including UnitedHealth Group, added hundreds of thousands of potentially questionable or unsupported diagnoses to patient records from 2018–2021, generating about $50 billion in extra federal payments over three years. Under the MA risk-adjustment system, private insurers receive higher reimbursements for enrollees diagnosed with serious, costly conditions. To capture these, insurers conduct home visits, review medical charts , and pay providers for record access. They can submit additional diagnoses beyond those from patients’ primary doctors, ostensibly to identify overlooked conditions. The WSJ found many such additions lacked follow-up treatment, contradicted treating physicians’ assessments, or were implausible. Indeed, CMS officials emphasized "improving payment accuracy and sustainability," tackling longstanding critiques that MA plans are overpaid by 20-30% relative to fee-for-service Medicare.Also, pragmatically, MA plans are also much more aggressive in prior authorization and care delays. This is something we deal with a consistent basis in practice. We can see the patients in clinic but often times it is very difficult to get approval for advanced tests or necessary surgery. This is coverage without actual clinical care.With MA enrolling over 54% of Medicare beneficiaries, the proposed 0.09% payment increase—far below the 4-6% analysts expected—could force plans to slash benefits, hike premiums, or exit markets. Seniors might face narrower networks, more prior authorization denials for procedures like fusions, and reduced extras , delaying care and worsening outcomes. From my operating room, this likely means more difficulty getting patients to surgery as they will be caught in the cost-cutting crossfire. Again, Medicare Advantage is notoriously difficult with
Unitedhealth Medicare Advantage Medicare Reform Unitedhealth Stock Unitedhealth Insurance Unitedhealth Medicare Advantage 2027 Medicare Rates Unitedhealthcare Insurance Humana Insurance
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Health Insurer Stocks Slide After Trump Administration Proposes Keeping Medicare Payment Rates SteadyThe Trump administration’s proposal would raise Medicare Advantage payment rates to insurers by 0.09% in 2027, well below Wall Street estimates of between 4-6%.
Read more »
Health insurance stocks tank on Trump proposal for flat Medicare Advantage reimbursementsStock prices for major insurers plummeted following the Trump administration's announcement of a flat Medicare Reimbursement rate in 2027.
Read more »
Achieve 20/20 Vision with Z-LasikManrique Custom Vision Center's Richard Doinoff discusses Z-Lasik, a quick and affordable solution for various vision problems, including nearsightedness, farsightedness, astigmatism, and the need for reading glasses. The procedure offers rapid recovery, and flexible payment plans are available.
Read more »
Trump administration announces 15 new drugs for Medicare price negotiation programThe Trump administration has unveiled 15 new drugs selected for a Medicare drug price negotiation program that allows the federal government to haggle directly with drug manufacturers.
Read more »
Trump administration announces 15 new drugs for Medicare price negotiation programNEW YORK (AP) — Drugs that treat Type 2 diabetes, HIV and arthritis are among 15 new medications chosen for a Medicare drug price negotiation program that
Read more »
Trump administration announces 15 new drugs for Medicare price negotiation programThe drugs include treatments for Type 2 diabetes, HIV, arthritis and various other conditions.
Read more »